PMID- 29755669
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 9
IP  - 29
DP  - 2018 Apr 17
TI  - A stitch in time saves nine: external quality assessment rounds demonstrate 
      improved quality of biomarker analysis in lung cancer.
PG  - 20524-20538
LID - 10.18632/oncotarget.24980 [doi]
AB  - Biomarker analysis has become routine practice in the treatment of non-small cell 
      lung cancer (NSCLC). To ensure high quality testing, participation to external 
      quality assessment (EQA) schemes is essential. This article provides a 
      longitudinal overview of the EQA performance for EGFR, ALK, and ROS1 analyses in 
      NSCLC between 2012 and 2015. The four scheme years were organized by the European 
      Society of Pathology according to the ISO 17043 standard. Participants were asked 
      to analyze the provided tissue using their routine procedures. Analysis scores 
      improved for individual laboratories upon participation to more EQA schemes, 
      except for ROS1 immunohistochemistry (IHC). For EGFR analysis, scheme error rates 
      were 18.8%, 14.1% and 7.5% in 2013, 2014 and 2015 respectively. For ALK testing, 
      error rates decreased between 2012 and 2015 by 5.2%, 3.2% and 11.8% for the 
      fluorescence in situ hybridization (FISH), FISH digital, and IHC subschemes, 
      respectively. In contrast, for ROS1 error rates increased between 2014 and 2015 
      for FISH and IHC by 3.2% and 9.3%. Technical failures decreased over the years 
      for all three markers. Results show that EQA contributes to an ameliorated 
      performance for most predictive biomarkers in NSCLC. Room for improvement is 
      still present, especially for ROS1 analysis.
FAU - Keppens, Cleo
AU  - Keppens C
AD  - University of Leuven, Department of Public Health and Primary Care, Biomedical 
      Quality Assurance Research Unit, Leuven, Belgium.
FAU - Tack, Veronique
AU  - Tack V
AD  - University of Leuven, Department of Public Health and Primary Care, Biomedical 
      Quality Assurance Research Unit, Leuven, Belgium.
FAU - Hart, Nils 't
AU  - Hart N'
AD  - University Medical Center Groningen, Department of Pathology, Groningen, The 
      Netherlands.
FAU - Tembuyser, Lien
AU  - Tembuyser L
AD  - University of Leuven, Department of Public Health and Primary Care, Biomedical 
      Quality Assurance Research Unit, Leuven, Belgium.
FAU - Ryska, Ales
AU  - Ryska A
AD  - Charles University Medical Faculty and University Hospital, Department of 
      Pathology, Hradec Kralove, Czech Republic.
FAU - Pauwels, Patrick
AU  - Pauwels P
AD  - Center for Oncologic Research (CORE), University of Antwerp, Antwerp, Belgium.
FAU - Zwaenepoel, Karen
AU  - Zwaenepoel K
AD  - University Hospital Antwerp, Department of Pathology, Edegem, Belgium.
FAU - Schuuring, Ed
AU  - Schuuring E
AD  - University Medical Center Groningen, Department of Pathology, Groningen, The 
      Netherlands.
FAU - Cabillic, Florian
AU  - Cabillic F
AD  - Cytogenetics and Cellular Biology Department, CHU de Rennes, Rennes, France.
AD  - INSERM, INRA, Universite Rennes 1, Universite Bretagne Loire, Nutrition 
      Metabolisms and Cancer, Rennes, France.
FAU - Tornillo, Luigi
AU  - Tornillo L
AD  - University of Basel, Basel, Switzerland.
AD  - GILAB AG, Allschwil, Switzerland.
FAU - Warth, Arne
AU  - Warth A
AD  - University Hospital Heidelberg, Heidelberg, Germany.
FAU - Weichert, Wilko
AU  - Weichert W
AD  - Technical University Munich (TUM), Munich, Germany.
FAU - Dequeker, Elisabeth
AU  - Dequeker E
AD  - University of Leuven, Department of Public Health and Primary Care, Biomedical 
      Quality Assurance Research Unit, Leuven, Belgium.
CN  - EQA assessors expert group
LA  - eng
PT  - Journal Article
DEP - 20180417
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5945546
OTO - NOTNLM
OT  - biomarker analysis
OT  - external quality assessment
OT  - molecular pathology
OT  - non-small cell lung cancer
OT  - targeted therapy
COIS- CONFLICTS OF INTEREST 't Hart N: Consulting fees and speaker honoraria from 
      Pfizer, Roche and unrestricted research grants from Roche and AstraZeneca. 
      Cabillic F: No conflict of interests to be declared. Bubendorf L: Consulting fees 
      and speaker honoraria from Abbott, Pfizer, Roche and Astra Zeneca. Dequeker E: An 
      unrestricted research grant was obtained from Pfizer Oncology. Keppens C: No 
      conflict of interests to be declared. Pauwels P: No conflict of interests to be 
      declared. Ryska A: Unrestricted research grants from AstraZeneca, Bristol Meyers 
      Squib, Merck, Boehringer Ingelheim, Roche and Pfizer Oncology. Schuuring E: 
      Consulting fees and speaker honoraria from Abbott, Novartis, Pfizer, BioCartis, 
      Illumina, AstraZeneca, Roche and Amgen; and unrestricted research grants. from 
      Boehringer Ingelheim, Biocartis and Roche. Tack V: No conflict of interests to be 
      declared. Tembuyser L: No conflict of interests to be declared. Tornillo L: No 
      conflict of interest to be declared. Warth A: No conflict of interest to be 
      declared. Weichert W: No conflict of interest to be declared. Zwaenepoel K: No 
      conflict of interests to be declared.
EDAT- 2018/05/15 06:00
MHDA- 2018/05/15 06:01
PMCR- 2018/04/17
CRDT- 2018/05/15 06:00
PHST- 2017/11/07 00:00 [received]
PHST- 2018/02/26 00:00 [accepted]
PHST- 2018/05/15 06:00 [entrez]
PHST- 2018/05/15 06:00 [pubmed]
PHST- 2018/05/15 06:01 [medline]
PHST- 2018/04/17 00:00 [pmc-release]
AID - 24980 [pii]
AID - 10.18632/oncotarget.24980 [doi]
PST - epublish
SO  - Oncotarget. 2018 Apr 17;9(29):20524-20538. doi: 10.18632/oncotarget.24980. 
      eCollection 2018 Apr 17.